Pandion Therapeutics Holdco LLC

Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA.

Cantel Medical

Coherent Corp

Lionheart Holdings

Perspecta Inc

NEW YORK, March 11, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cantel Medical Corp. (NYSE: CMD) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to STERIS plc for approximately $16.93 in cash and 0.33787 STERIS ordinary shares for each Cantel common share. If you are a Cantel shareholder, click here to learn more about your rights and options.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates CMD, COHR, PRSP, CUB, PAND; Shareholders are Encouraged to Contact the Firm

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Pandion Therapeutics, Inc. - PAND

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER

Pandion Therapeutics Inc (NASDAQ: PAND) shares closed over 133% higher today. What Happened: Pandion — a developer of novel therapeutics targeting autoimmune diseases — will be acquired by a subsidiary of drug multinational Merck & Co, Inc (NYSE: MRK), according to a statement issued Thursday.

Why Pandion Therapeutics Stock Shot Up 133% Today

Merck

You'd vault into the air too if a big-name pharmaceutical paid a high premium for your stock.

Why Pandion Therapeutics Stock Blasted Sky-High on Thursday

Seeking to beef up a product line dominated by the cancer drug Keytruda, Merck & Co. Inc. (NYSE:MRK) has made another in a series of acquisitions. The Kenilworth, New Jersey-based drug giant is paying nearly $2 billion to acquire Pandion Therapeutics Inc. (NASDAQ:PAND), a Watertown, Massachusetts-based biotech developing drugs for autoimmune diseases.

Merck Makes Another Move to Beef Up Drug Business

Pandion Therapeutics stock blasted to a record high Thursday on Merck's plan to buy the IPO stock for $1.85 billion. Pandion just recently wrapped its initial public offering in July.

Pandion Therapeutics Surges To Record High On Merck's $1.85 Billion Buyout

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. ("Pandion" or the "Company") (NASDAQ: PAND) in connection with the proposed all-cash acquisition of...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pandion Therapeutics, Inc. (NASDAQ: PAND) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Merck & Co., Inc. (NYSE: MRK).

PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders. Under the terms of the agreement, Pandion shareholders will receive $60.00 per share in cash. Halper Sadeh encourages Pandion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalpe

Pandion Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Pandion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PAND

Pandion Therapeutics (PAND) stock is soaring higher on Thursday after announcing that Merck (MRK) plans to acquire the biotechnology company. The post PAND Stock: Why Pandion Therapeutics Shares Have Skyrocketed Today appeared first on InvestorPlace.

PAND Stock: Why Pandion Therapeutics Shares Have Skyrocketed Today

Merck sparked a 132% surge in Pandion Therapeutics on Thursday after the pharmaceutical giant agreed to acquire the biotech firm for $1.85 billion. Pandion is a clinical-stage biotechnology company that is developing therapeutics for patients living with autoimmune diseases. Pandion's lead candidate, PT101, completed a Phase 1a trial earlier this year and is a potential treatment for ulcerative colitis.

Pandion Therapeutics soars 132% after Merck agrees to buy the biotech for $1.85 billion

Pharma deals slowed down last year partly due to Covid impact.

Merck Agrees To Acquire Pandion Therapeutics Amid Expectations Of Rebound In Pharma M&A This Year

Merck (NYSE: MRK) is buying Pandion Therapeutics, Inc. (Nasdaq: PAND) in a deal valued at $1.85 billion. These are the details.

Merck (MRK) To Buy Pandion Therapeutics (PAND) In $1.85 Billion Deal

Merck & Co. announced an agreement Thursday to buy Pandion Therapeutics Inc. in a deal valued at $1.85 billion. Under terms of the deal, Merck will pay $60 in cash for each Pandion share outstanding, which represents a 134.1% premium to Wednesday's closing price.

Merck to buy Pandion Therapeutics for 134% premium

WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Company's tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes (nPOD) 13th Annual Scientific Meeting. The research, done in collaboration with St Vincent's Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.

Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.

Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Pandion has a unique technology platform that can enable template-like design of protein therapeutics to treat autoimmunity.

Pandion Therapeutics: Biologics Platform For Autoimmunity

-Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases -PT101 maintained selectivity for regulatory T cells at all doses tested -Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021 -Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion's board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company's board on December 2, 2020.

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

- Enrollment and dosing complete in Phase 1a clinical trial of PT101 ; top-line results expected early 2021 - PT627 s ystemic PD-1 agonist development candidate nominated; IND-enabling studies expected to initiate 4Q 2020 - Presented preclinical data at FOC I S 2020 highlighting potential of TALON platform in autoimmune disease

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:00 p.m. ET.

Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies (FOCIS) 2020 virtual annual meeting.

Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

WATERTOWN, Mass., Sept.  24, 2020  (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m. ET.

Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit

WATERTOWN, Mass., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a fireside chat at the upcoming Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17th, 2020 at 2:00 p.m. ET.

News for Pandion Therapeutics Holdco LLC Stock (PAND)